Dr. Mayer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5151 Highway 90
Sierra Vista, AZ 85650
Summary
- Dr. Stephen Mayer is a well-respected oncologist currently caring for patients in Southern Arizona. He specializes in the study and treatment of specific conditions like amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. His educational background includes a Fellowship in Hematology and Medical Oncology, a Residency and Internship in Internal Medicine from Beth Israel Deaconess Medical Center, an MD from Boston University School of Medicine, a BS in Biology from Loyola Marymount University, and a PhD in Biochemistry from The University of Arizona. Dr. Mayer has taken various roles from oncology practice in hospitals, teaching at Harvard Medical School, to instructing in prison campuses. His significant contributions to research have been published and cited in renowned medical journals. He also received FACP recognition from ACP and CMS Meaningful Use Stage 1 Certification from RcopiaMU EHR.
Education & Training
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2001 - 2002
- Boston University School of MedicineClass of 2001
- The University of ArizonaPhD, Biochemistry, 1990
- Loyola Marymount UniversityBS, Biology, 1983
Certifications & Licensure
- AZ State Medical License 2024 - 2025
- CO State Medical License 2015 - 2025
- MA State Medical License 2003 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- FACP ACP, 2015
- CMS Meaningful Use Stage 1 Certification RcopiaMU EHR, DrFirst.com, Inc., 2013
- Member Alpha Omega Alpha, 2000
- Join now to see all
Publications & Presentations
PubMed
- 31 citationsEnhancer elements activate the weak 3' splice site of alpha-tropomyosin exon 2.Billy T. Dye, Massimo Buvoli, Stephen A. Mayer, Chorng-Horng Lin, James G. Patton
RNA. 1998-12-01 - 276 citationsCharacterization and molecular cloning of polypyrimidine tract-binding protein: a component of a complex necessary for pre-mRNA splicing.James G. Patton, Stephen A. Mayer, Paul Tempst, Bernardo Nadal-Ginard
Genes & Development. 1991-07-01 - 28 citationsFunctional crosstalk between exon enhancers, polypyrimidine tracts and branchpoint sequencesMassimo Buvoli, Stephen A. Mayer, James G. Patton
The EMBO Journal. 1997-12-01
Abstracts/Posters
- Isolation of a novel U-PA binding protein from human platelet membraneJiang, Y, S. Mayer and V. Gurewich, XIIIth International Congress on Fibrinolysis and Thrombolysis, Barcelona, Spain, 6/24/1996
- U1 snRNP interacts with the branchpoint-polypyrimidine tract of mammalian intronsMayer, S.A., J.G. Patton and B. Nadal-Ginard, Cold Spring Harbor Laboratory Symposium on RNA Processing, Cold Spring Harbor, NY, 5/15/1991
- Join now to see all
Lectures
- tropomyosin alternative 3' splice site selection is based on U1 snRNP-pyrimidine tract interactions in an ATP independent complexCold Spring Harbor, NY - 5/17/1993
- U1 snRNP is associated with the branchpoint-polypyrimidine tract of mammalian introns in an ATP independent complexKeystone, CO - 5/27/1992
Press Mentions
- Valley View’s Calaway-Young Cancer Center Welcomes New Oncologist and Hematologist Dr. Stephen MayerJune 9th, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: